ProPhase Labs Inc. (PRPH) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for PRPH in the last 30 days. The most recent was published Aug 19, 2026.
Price$0.36+0.00 (+0.00%)
2026-07-302026-10-30
News · 26 weeks80%
2026-05-032026-10-25
Mix390d
- SEC Filings2(67%)
- Other1(33%)
Latest news
25 items- SECSEC Form 10-Q filed by ProPhase Labs Inc.10-Q - ProPhase Labs, Inc. (0000868278) (Filer)
- SECSEC Form NT 10-Q filed by ProPhase Labs Inc.NT 10-Q - ProPhase Labs, Inc. (0000868278) (Filer)
- SECProPhase Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - ProPhase Labs, Inc. (0000868278) (Filer)
- SECAmendment: SEC Form 10-Q/A filed by ProPhase Labs Inc.10-Q/A - ProPhase Labs, Inc. (0000868278) (Filer)
- SECAmendment: SEC Form 10-Q/A filed by ProPhase Labs Inc.10-Q/A - ProPhase Labs, Inc. (0000868278) (Filer)
- SECSEC Form 10-Q filed by ProPhase Labs Inc.10-Q - ProPhase Labs, Inc. (0000868278) (Filer)
- SECSEC Form 10-K filed by ProPhase Labs Inc.10-K - ProPhase Labs, Inc. (0000868278) (Filer)
- SECSEC Form NT 10-Q filed by ProPhase Labs Inc.NT 10-Q - ProPhase Labs, Inc. (0000868278) (Filer)
- PRProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform$201.2 Million in Gross Claims with Expanding Settlement Activity Across Multiple Insurance Carriers Active Negotiations Support Estimated $50–$60 Million Net Recovery and Near-Term Cash Flow Potential UNIONDALE, NY, April 15, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today reported its financial results for the year ended December 31, 2025 and provided a business update highlighting continued advancement and expansion of its Crown Medical Collections initiative. "We are very encouraged by the scale and progression of activity across our receivables platform," said Ted Karkus,
- SECSEC Form NT 10-K filed by ProPhase Labs Inc.NT 10-K - ProPhase Labs, Inc. (0000868278) (Filer)
- PRProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections ActivityInstitutional Financing Interest Emerges for Receivables-Backed Financing Following Extensive Diligence UNIONDALE, NY, March 17, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today provided a business update regarding its Crown Medical Collections initiative and related strategic activities. "We are encouraged by the level of engagement across a broad group of insurance payors and by how these discussions continue to advance," said Ted Karkus, Chief Executive Officer of ProPhase Labs. "The progression we are seeing, together with Crown Medical's demonstrated experience in resolving
- SECProPhase Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ProPhase Labs, Inc. (0000868278) (Filer)
- SECProPhase Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ProPhase Labs, Inc. (0000868278) (Filer)
- PRProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections InitiativeEach Initiative Has the Potential to Drive Significant Liquidity and Strengthen the Company's Balance Sheet UNIONDALE, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today announced that it has initiated a potential sale or strategic partnership process for BE-Smart™, its clinically validated esophageal cancer risk stratification test, and is advancing its Crown Medical Collections initiative, with each initiative independently offering the potential to drive significant liquidity and materially strengthen the Company's balance sheet. BE-Smart™ Sale and Strategic Partne
- PRJoin ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on February 3rdUNIONDALE, NY, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC:PRPH) ("ProPhase" or the "Company") is pleased to invite investors to a webinar on Tuesday, February 3, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature ProPhase Labs Chairman and CEO Ted Karkus. Attendees will gain an in-depth look at ProPhase's dynamic portfolio of high-growth healthcare assets spanning molecular diagnostics, genomics, and consumer health. Karkus will highlight recent milestones, including full U.S. patent approval and clinical validation of its BE-Smart™ Esophageal Cancer Test, a groundbreaking diagnostic designed for early cancer detection in a $7–14 billion
- SECProPhase Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ProPhase Labs, Inc. (0000868278) (Filer)
- PRProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement PostureUNIONDALE, NY, Jan. 26, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today provided an operational update on the progress of its Crown Medical Collections initiative relating to legacy COVID-19 testing receivables held by its laboratory subsidiaries currently in Chapter 11 proceedings. Crown Medical Collections ("Crown Medical"), which serves as special counsel to the Debtors for the collection of accounts receivable, is actively engaged in settlement negotiations with a broad group of commercial insurance payors in connection with outstanding ProPhase receivables arising from appr
- SECProPhase Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ProPhase Labs, Inc. (0000868278) (Filer)
- SECProPhase Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - ProPhase Labs, Inc. (0000868278) (Filer)
- PRProPhase Labs Uplists from Pink Sheets to OTC MarketUNIONDALE, NY, Jan. 22, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. ("ProPhase" or the "Company"), a diversified life sciences and diagnostics company, today announced that its common stock has been approved and uplisted from the Pink Sheets to the OTC market. "We are pleased to have completed this uplisting from the Pink Sheets to the OTC market," said Ted Karkus, Chairman and Chief Executive Officer of ProPhase Labs. "We believe the coming weeks will mark an important inflection point for ProPhase Labs. We continue to see encouraging momentum in our Crown Medical collections initiative, and we plan to provide a positive operational update on that effort very shortly. We also plan to pr
- SECProPhase Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ProPhase Labs, Inc. (0000868278) (Filer)
- SECProPhase Labs Inc. filed SEC Form 8-K: Leadership Update8-K - ProPhase Labs, Inc. (0000868278) (Filer)
- PRProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset ValueUNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC:PRPH) today provided an update to shareholders regarding recent trading activity, its capital structure, and the Company's underlying asset base. The Company believes that recent volatility in its stock price has been driven by a combination of short-term technical factors, including the accelerated conversion and resale of a significant portion of its outstanding convertible debt, the completion of a 1-for-10 reverse stock split, and the Company's transition from Nasdaq to the OTC market. In aggregate, more than $3.3 million of principal has been converted (out of a total of $3.8 million principal at issuance),
- SECProPhase Labs Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - ProPhase Labs, Inc. (0000868278) (Filer)
- SECSEC Form 424B5 filed by ProPhase Labs Inc.424B5 - ProPhase Labs, Inc. (0000868278) (Filer)
PRPH FAQ
7 questionsWhat does ProPhase Labs Inc. do?
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production...What is the latest news on PRPH?
Quantisnow has not tracked any new filings, ratings or press releases for PRPH in the last 30 days. The most recent wire item was published on August 19, 2026.Where does PRPH stock trade?
ProPhase Labs Inc. (PRPH) is listed on NASDAQ.What sector and industry is PRPH in?
ProPhase Labs Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PRPH?
ProPhase Labs Inc. has had 3 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $1500.00 price target on 2022-01-14. Recent price targets range from $1200.00 to $1500.00.What companies are similar to PRPH?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PRPH side-by-side with any of them on Quantisnow.How can I track PRPH on Quantisnow?
Quantisnow aggregates ProPhase Labs Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRPH to receive live email and push alerts on every new disclosure.